(特集：PIVMECILLINAMによる尿路感染症の治療) 内科領域における急性単純性膀胱炎に対するPivmecillinam(メリシン錠)の臨床効果

概要

論文の詳細を見る
Efficasy and safety of pivmecillinam on acute simple cystitis in the field of internal medicine was evaluated according to Criteria for Clinical Evaluation in Urinary Tract Infection' recommended by The Japan Society of Chemotherapy. 200 mg of pivmecillinam was administered daily for 3 to 4 days in principle to 76 cases. Among the 76 cases, efficacy evaluation was made in 41 cases according to the criteria while adverse reactions were evaluated in all the 76 cases. (1) Effective rate on pain on urination, pyuria and bacteriuria was 97.6%, 90.3% and 32.9%, respectively. Overall clinical efficacy rate by the aforementioned criteria was 97.6%. (2) Regarding causative organisms, E. coli isolated in 63.3% cases and eradication rate was 81.8%. 13 strains of ABPC-resistant E. coli were isolated and II strains out of them were eradicated. (3) Side effects were observed in 3 cases (3.9%) and the abnormal changes of laboratory findings were observed in 8 cases (10,5%), all of which were, however, mild ones. Thus, pivmecillinam seems to be useful agent for treatment of acute simple cystitis.
泌尿器科紀要刊行会の論文